Dornier names new president
Dornier Medical Systems of Kennesaw, GA, has a new management team in place. COO James Haisler has added the title of president to his duties, replacing Karl Jonietz, who has left Dornier to pursue other opportunities.Other new members of the DMSI team
Dornier Medical Systems of Kennesaw, GA, has a new management team in place. COO James Haisler has added the title of president to his duties, replacing Karl Jonietz, who has left Dornier to pursue other opportunities.
Other new members of the DMSI team include Manfred Drax, vice president of finance and administration; John McCauley, director of marketing; Tom Gibson, director of national service; and Bryan Smith, director of lithotripsy.
In other news, the company's Dornier Surgical Products subsidiary is conducting pilot studies on its Image Analysis System (IAS), which is designed to improve the treatment and detection of prostate disease. IAS allows physicians to see the extent of tissue destruction beneath the surface using existing ultrasound systems and Dornier's analysis console. The technique holds promise for identifying cancer within the prostate and in guiding the administration of transrectal biopsy, according to the company.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
